Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMELOT: Quetiapine vs Pimavanserin in Lewy Body Disease Psychosis
NCT05590637Phase 4Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Apr 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pimavanserin in Parkinson's disease (PD), dementia with Lewy bodies (DLB), sponsored by UT Health San Antonio. Started Apr 2022; status: recruiting.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT05590637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05590637.